Lynk Pharmaceuticals Reaches Key Clinical Milestone as First Participant Receives BLKR201 in Phase 1 Trial

Lynk Pharmaceuticals has announced an important step forward in the development of its investigational drug BLKR201, originally known as LNK01006. The milestone comes after its global partner, Formation Bio, successfully dosed the first participant in a Phase 1 clinical trial.

The study marks the first time BLKR201 is being tested in humans and could open new possibilities for treating neurological, autoimmune, and inflammatory diseases.

First-in-Human Trial Officially Begins

Formation Bio has started the Phase 1 clinical trial known as BLKR201-101-HV by dosing the first healthy volunteer.

The study is designed to evaluate the safety, tolerability, and pharmacological profile of BLKR201 through:

• Single Ascending Dose (SAD)
• Multiple Ascending Dose (MAD)

The trial is being conducted in healthy volunteers, and initial data from the study is expected in early 2027.

This is an important stage in drug development because it helps researchers understand how the drug behaves in the human body before moving into larger patient studies.

What Is BLKR201?

BLKR201, previously called LNK01006, is a novel selective TYK2 inhibitor designed to penetrate the central nervous system (CNS).

TYK2 is a well-established target involved in immune system signaling. By selectively targeting this pathway inside the brain and central nervous system, BLKR201 may have the potential to treat a variety of conditions linked to inflammation and immune dysfunction.

The drug has been specifically engineered to provide:

• High target selectivity
• Strong metabolic stability
• Effective CNS penetration

These characteristics may help the therapy deliver targeted effects while reducing unwanted interactions with other biological pathways.

Why TYK2 Matters in Drug Development

TYK2 plays a key role in immune signaling and has become an increasingly important target in autoimmune and inflammatory disease research.

Many existing therapies focus on controlling immune responses throughout the body. BLKR201 takes a different approach by targeting immune activity within the central nervous system.

Researchers believe this strategy could potentially create opportunities in several disease areas, including:

• Neurological disorders
• Autoimmune diseases
• Chronic inflammatory conditions

While the clinical potential is still being evaluated, the drug's unique design has attracted significant attention.

Lynk Pharmaceuticals Highlights the Milestone

Dr. Zhao-Kui (ZK) Wan, Founder, Chairman, and Chief Executive Officer of Lynk Pharmaceuticals, described the initiation of the study as an important step in the global development of BLKR201.

According to Dr. Wan, the rapid advancement of the program demonstrates both the strength of the original scientific discovery and the efficiency of Formation Bio's development model.

He also expressed confidence that the program could continue to expand into multiple therapeutic areas while addressing significant unmet medical needs.

Partnership Between Lynk Pharmaceuticals and Formation Bio

The clinical advancement follows a major licensing agreement signed in December 2025.

Under the agreement, Lynk Pharmaceuticals granted exclusive development and commercialization rights for LNK01006 outside Greater China to Bleecker Bio, a subsidiary of Formation Bio.

As part of the deal, Lynk Pharmaceuticals received:

• An upfront payment
• A minority equity stake in Bleecker Bio
• Eligibility for development, regulatory, and commercial milestone payments worth up to $605 million
• Tiered royalties on future product sales

The partnership allows Formation Bio to leverage its technology-driven development model while advancing the program globally.

Formation Bio's AI-Driven Development Approach

Formation Bio is known for combining artificial intelligence with pharmaceutical development to accelerate clinical programs.

The company focuses on improving the speed and efficiency of drug development by using technology platforms, data analytics, and AI-powered processes throughout the clinical development journey.

Its business model involves partnering with, acquiring, or licensing promising drug candidates and advancing them through clinical development with the goal of bringing new therapies to patients faster.

The development of BLKR201 is one of the latest examples of this strategy in action.

About Lynk Pharmaceuticals

Lynk Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for autoimmune and inflammatory diseases.

The company was founded by experienced research and development leaders from major pharmaceutical organizations, including Pfizer, MSD, and Johnson & Johnson.

Its research efforts focus on several advanced therapeutic areas, including:

• JAK-STAT signaling pathways
• TYK2-targeted therapies
• Targeted protein degradation technologies

Lynk combines AI-assisted drug design, biological evaluation platforms, translational research, and clinical development capabilities to build new treatment options for patients worldwide.

Over the years, the company has successfully advanced multiple drug candidates through internal research programs and strategic global partnerships.

Looking Ahead

The first patient dosing in the BLKR201 Phase 1 trial marks a significant milestone for both Lynk Pharmaceuticals and Formation Bio.

With its unique CNS-penetrant TYK2 inhibition approach, BLKR201 represents a new direction in the treatment of autoimmune, inflammatory, and neurological diseases. As the Phase 1 study progresses and data becomes available in 2027, researchers will gain a clearer understanding of the drug's safety profile and future clinical potential.

For now, the start of human testing is an important first step in determining whether BLKR201 can become a new treatment option for patients facing complex immune-related disorders.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!